MedTrace Logo

Exparel Use in Peripheral Nerve Blocks and Local Infiltration for Foot and Ankle Surgery

NCT05494645 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2026-04-28

No results posted yet for this study

Summary

Liposomal Bupivacaine (Exparel) has been recently studied as the active agent utilized in various nerve block. Due to its liposomal form allowing for extended delivery, Exparel has been used in various peri-operative nerve blocks among multiple orthopaedic specialties in hopes of achieving improved pain control and decreased opioid use. This study compares the efficacy and effect on opioid use of peripheral nerve blocks and local infiltration with and without Exparel in patients undergoing foot and ankle surgery.

Conditions

  • Pain, Postoperative
  • Pain, Acute Postoperative
  • Ankle Fractures
  • Ankle Injuries and Disorders

Interventions

DRUG

Exparel

Liposomal bupivicaine

DRUG

Peripheral Nerve Block

Peripheral nerve block without Exparel

Sponsors & Collaborators

  • St. Luke's Hospital, Pennsylvania

    lead OTHER

Principal Investigators

  • Anna Ng-Pellegrino · St. Luke's Hospital and Health Network, Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-01-31
Completion
2023-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494645 on ClinicalTrials.gov